Edition:
United Kingdom

Acer Therapeutics Inc (ACER.OQ)

ACER.OQ on NASDAQ Stock Exchange Capital Market

2.89USD
17 Jul 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.89
Open
$3.00
Day's High
$3.10
Day's Low
$2.88
Volume
68,048
Avg. Vol
56,332
52-wk High
$34.10
52-wk Low
$2.88

About

Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The... (more)

Overall

Beta: 1.48
Market Cap(Mil.): $30.16
Shares Outstanding(Mil.): 10.09
Dividend: --
Yield (%): --

Financials

  ACER.OQ Industry Sector
P/E (TTM): -- 98.29 34.16
EPS (TTM): -2.71 -- --
ROI: -89.28 7.71 12.64
ROE: -89.67 8.16 17.19

FDA declines to approve Acer Therapeutics' rare genetic disorder treatment

Acer Therapeutics Inc said on Tuesday the U.S. Food and Drug Administration declined to approve its treatment for a severe, rare genetic disorder that can cause blood vessels to fatally rupture, sending its shares plunging as much as 78%.

25 Jun 2019

UPDATE 2-FDA declines to approve Acer Therapeutics' rare genetic disorder treatment

June 25Acer Therapeutics Inc said on Tuesday the U.S. Food and Drug Administration declined to approve its treatment for a severe, rare genetic disorder that can cause blood vessels to fatally rupture, sending its shares plunging as much as 78%.

25 Jun 2019

FDA declines to approve Acer Therapeutics' treatment for rare genetic disorder

June 25Acer Therapeutics Inc said on Tuesday its treatment for a severe, rare genetic disorder that can cause blood vessels to fatally rupture was declined approval from the U.S. Food and Drug Administration.

25 Jun 2019

Earnings vs. Estimates